AVVie and the EIC Accelerator: A Mitral Implant Still Preclinical
When the mitral valve leaks, blood flows backwards in the heart, and AVVie's EIC report says about 13 million people in Europe and the US have been diagnosed with this mitral regurgitation, and that fewer than 5% of patients with moderate to severe disease receive treatment. AVVie, registered in Vienna in 2018 and led by Werner Mohl, a cardiac surgeon at Vienna General Hospital, developed the Mitral Butterfly: a Nitinol frame with an artificial leaflet mesh that is folded into a catheter, anchored in the heart and holds back the valve's prolapsing rear leaflet, according to its EIC project.
The European Innovation Council granted €2,499,999 towards an €8.7 million project from February 2023 to January 2025. The final-period report says the team "demonstrated in the bench the feasibility of deployment", refined the implant and completed an initial hazard analysis, with design freeze scheduled after the newly designed devices are implanted in chronic animals. The Austrian research agency FFG says preclinical studies in animals have run since 2023 and must be completed before clinical trials. Register publications shown by North Data record Institut Allergosan leaving as shareholder in April 2025; P+F Products + Features GmbH acquired AVVie in August 2026, when it was registered as the sole listed shareholder, replacing the previous one.
Company file
- Legal entity
- AVVie GmbH, FN 501418f, Vienna
- Registered
- 13 November 2018
- Founder
- Werner Mohl, cardiac surgeon
- Product
- Mitral Butterfly posterior leaflet augmentation implant
- Shareholder
- P+F Products + Features GmbH since August 2026; Institut Allergosan until April 2025
- EIC project
- Angelvalve Project, 1 Feb 2023 to 31 Jan 2025
- EIC funding
- Grant first
Where AVVie Stands Now
AVVie's news page lists the EIC grant in January 2023, an FFG life sciences grant, conference presentations at EuroPCR, TVT and London Valves in 2023, and a new project manager in November 2024, its most recent item. Sources reviewed on 4 November 2026 show no announced first-in-human study, regulatory submission or equity round. The register shows a change of shareholder in August 2026 and share capital of €50,000; North Data shows no insolvency notice.
The record
A heart valve implant still in animal studies
AVVie had completed a 90-day animal safety trial before its EIC award. The EIC project ended with design freeze still waiting on further chronic animal tests; in August 2026 a new shareholder took over.
- Nov 2018Company registeredVienna, founded by cardiac surgeon Werner Mohl
- Jan 202090-day animal trialCompany reports safety endpoints met
- Jun 2022EIC Accelerator cut-offMitral Butterfly: transcatheter mitral valve repairgrant first
- Feb 2023EIC project starts€8.7M project€2.50M grant
- Apr 2023FFG grantSelected for Austrian Life Sciences programme
- Jan 2025EIC project endsBench feasibility; design freeze pending chronic animal tests
- Aug 2026New ownerP+F Products + Features GmbH registered as shareholder; Institut Allergosan left in April 2025
PR Newswire, CORDIS, AVVie and North Data.
"We are pleased to reach this important milestone in line with our ambitious development plan."
Werner Mohl, founder, AVVie, January 2020, on the 90-day animal trialThe Technology: A Hemi-Valve by Catheter
Instead of replacing the whole valve, the Mitral Butterfly supports the malfunctioning rear leaflet while leaving the front leaflet to work normally. In January 2020 AVVie reported a 90-day chronic animal safety trial with no device-related adverse effects over an average of 12 million heart cycles per animal. The EIC project worked on the catheter-delivered version, and the report found that two to three sizes for each of the two main forms of the disease would be enough.
The problem
Mitral regurgitation in Europe and the US, per the EIC report
The report says about 13 million people in Europe and the US have been diagnosed with mitral regurgitation, and fewer than 5% of patients with moderate to severe disease receive treatment. It does not give the size of that group.
CORDIS project 190163567, final report.
What the EIC Project Promised, and What CORDIS Shows
The EIC project
EU contribution: 29% of an €8.7M project
The Angelvalve Project ran from February 2023 to January 2025. CORDIS lists it as closed. It does not show how the other project costs were financed.
CORDIS project 190163567. Values in € millions.
The project was to advance transcatheter mitral valve repair with the Mitral Butterfly. It produced a testing rig, a refined design, bench proof of deployment and a risk analysis. It did not reach design freeze, which was waiting on more chronic animal tests, and it planned new patent filings. CORDIS lists the project as closed.
- Bench deploymentShownPer final report.
- Risk analysisDoneISO 14971.
- Design freezeNot reachedPending animal tests.
- First-in-humanNot announcedNone announced.
The Money
The other 71% of the €8.7 million budget is other project costs; CORDIS does not show how they were financed. AVVie's accounts are filed in Austria but not freely displayed, and sources reviewed show no announced outside funding round. Its former shareholder, Institut Allergosan, and the new one, P+F Products + Features, have not published the terms of the change.
What Cannot Be Checked
Questions for the EIC
Whether the chronic animal tests were completed, when a human study will start, how the €6.25 million in other project costs was financed, and what the change of owner means for the project are not public.
Why Europe Should Care
The EIC backed a Vienna surgeon's alternative design for catheter-based valve repair. More than three years after the June 2022 cut-off, sources reviewed show no announced human study, and the company's registered shareholder has changed.
What the project promised
To advance transcatheter mitral valve repair with the Mitral Butterfly towards the clinic.
What the record shows
Bench feasibility and design work, no design freeze, no human study and a new owner in 2026.
The Verdict
Still on the bench
AVVie used the EIC money for engineering and risk work. It has announced no human use of the Mitral Butterfly, and its news page has no item after November 2024.
AVVie and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.
Industry
HealthMedical devices
- Focus
- Cardiovascular devices
- Technologies
- Transcatheter implantation
- Shape-memory alloys
- Keywords
- Mitral regurgitation
- Heart valves
- Structural heart disease